AML, ASPHO Flashcards
what are the BIG FOUR cytogen anomalies in AML?
t(8;21)= AML1-ETO;
inv (16)/t16;16) CBFB MYH11;
t(15;17) PML-RARA, variants
abnormal 11q23 MLL-partner
characteristics of AML with t(8;21)?:
Auer rods, chloromas, good prognosis
characteristics of AML with inv(16)/t(16;16)?
Eos with baso granules, chloromas, good prog
characteristics of AML with (15;17)?
granules/auer rods, DIC, bleeding, good prog with ATRA/arsenic
characteristics of AML with 11q23?
infant WBC/skin/CNS/gums t-AML after top II inh
in APML, cells blocked where during dev?
promeylocyte
what does ATRA do in AML?
overcomes the “differentiation block” at the promyelocyte stage
Give 5 major myeloid luekemia predispositions
Germline mutations in CEBPA, DDX41, RUNX1, ANKRD26, ETV6, GATA2…also bone marrow failure syndromes (fanconi anemia, Dyskeratosis congenita), T21, NF1 (JMML), Noonan (JMML)
2 marrow failure syndromes–> pancytopenia taht are associated with MDS/AML
Fanconi anemia, Dyskeratosis congenita
marrow failure syndrome–> anemia associated with MDS?
Diamond Blackfan Anemia
marrow failure syndrome–> neutropenia associated with MDS?
Schwachman-Diamond, Kostmann Syndrome
marrow failure syndrome–> thrombocytoepnia associated with MDS/AML?
congenital amegakaryocytic thrombocytopenia (MPL mutation)
environemntal causes of AML?
alkylating agents, radiation, toposiomerase II inhibitors (etoposide> anthracyclines)
What is the difference in latency between AML caused by different environemntal agents?
alkylating agents and radiation: 5-7 years from exposure, common preceding MDS
topoisomerase II inhibitors: short latency (1-2 years) from exposure, rare preceding MDS
give the diff in cytogenetics between AML caused by different envrionemntal agents?
alkylating agents and radiation: monosomy 7, 7q deletions, monosomy 5, 5q deletions
topoisomerase II inhibitors: 11q23 rearrangement most common, but t(8;21), t(15;17), t(9;22), and inv(16) can also occur
what tends to be more refractory to treatment? treatment-related AML/MDS or de novo AML/MDS?
treatment-related
AML and CML are most common in what age group?
> 50 years
concordance rate of AML/ALL in identical twins= monozygotic?
depends on age of first twin when diagnosed…<1 year: close to 100% concordance (suggests prenatal preleuekmic event= KMT2A and intrauterine transfer)….age 1-5: 10-20% concordance, most = clonal, longer-latency between twins A and B…likely a prenatal preleuk event (ETV6-RUNX1, RUNX1T1, eg, intrauterine transfer); relatively lower risk of cooperating hits (unlike KMT2A)….case 6+: minimal increased risk
concordance for ALL/AML in fraternal twins?
minimal increased risk
In AML, is age used to risk stratify? gender? race? BMI? pharmacogenomics? high WBC?
No for all…except WBC>10k is high risk in APL–> use anthracycline or gemtuzumab immediately….but note that non-whites have inferior survival, under-BMI and over-BMI have inferior survival as well
Give 4 favourable risk stratifiers in AML
T21 (esp if <4); APL with t(15;17); inv (16) or t(8;21); NPM1 or CEBPA mutations
Give 4 unfavourable risk stratifiers in AML
treatment-related AML, MDS-related AML, monosomy 7, 5 q deletion, abnormal 3q, FT3/ITD especially if high allelic ratio (0.4+), mutation, primary induction failure =>5% blasts after course 2
Intermediate risk AML can be subclassified into favourable or unfavourable how?
MRD by flow cytometry after first block of therapy…using threshold of 0.1%
describe M0 AML
“aml without differentiation”…not differentiated, no MPO expressed